Fund Holdings — Cormorant Asset Management, LP

Total Portfolio Value
$1.76B
Total Bought
$188.34M
Total Sold
$602.68M
Net Transaction
-$414.34M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
PRAXIS PRECISION MEDICINES I(PRAX)1,000,000950,000-50,00053,000280,00315.87%+227,003
OLEMA PHARMACEUTICALS INC(OLMA)02,750,000+2,750,000068,7503.90%+68,750
MOONLAKE IMMUNOTHERAPEUTICS(MLTX)1,994,1734,355,433+2,361,26014,29857,4053.25%+43,106
EYEPOINT INC(EYPT)8,325,0008,265,000-60,000118,548151,0028.56%+32,454
ALUMIS INC2,147,3963,635,596+1,488,2008,56835,4832.01%+26,915
ASCENDIS PHARMA A/S(ASND)0100,000+100,000021,3241.21%+21,324
ENGENE HOLDINGS INC
COM
2,323,5954,000,000+1,676,40515,87036,1202.05%+20,250
BRIDGEBIO PHARMA INC(BBIO)1,400,0001,200,000-200,00072,71691,7885.20%+19,072
BRIGHT MINDS BIOSCIENCES INC(DRUG)1,059,3311,059,331064,25982,6704.69%+18,411
BRIDGEBIO ONCOLOGY THERAPEUT(BBOT)17,878,59417,878,5940207,034223,84012.69%+16,806
ABIVAX SA(ABVX)1,950,0001,350,000-600,000165,555182,05410.32%+16,499
EDGEWISE THERAPEUTICS INC(EWTX)4,010,0003,285,000-725,00065,04281,5174.62%+16,475
BIOAGE LABS INC(BIOA)2,140,6052,040,605-100,00012,58726,9971.53%+14,410
MBX BIOSCIENCES INC(MBX)1,225,0001,120,000-105,00021,43835,3252.00%+13,887
COGENT BIOSCIENCES INC(COGT)0225,000+225,00007,9920.45%+7,992
ORUKA THERAPEUTICS INC(ORKA)533,340533,340010,25616,1660.92%+5,909
TARSUS PHARMACEUTICALS INC(TARS)300,000250,000-50,00017,82920,4701.16%+2,641
AXSOME THERAPEUTICS INC(AXSM)100,00075,000-25,00012,14513,6980.78%+1,553
BIOHAVEN LTD(BHVN)10,00010,00001501130.01%-37
ARCUTIS BIOTHERAPEUTICS INC(ARQT)775,000500,000-275,00014,60914,5200.82%-89
VAXCYTE INC(PCVX)175,000125,000-50,0006,3045,7680.33%-536
AMYLYX PHARMACEUTICALS INC(AMLX)500,000400,000-100,0006,7954,8320.27%-1,963
CABALETTA BIO INC(CABA)5,000,0004,400,000-600,00011,7009,6360.55%-2,064
CRINETICS PHARMACEUTICALS IN(CRNX)400,000300,000-100,00016,66013,9650.79%-2,695
RAPPORT THERAPEUTICS INC(RAPP)3,192,5213,027,521-165,00094,81891,8555.21%-2,963
PHARVARIS N V
COM
1,363,2001,083,000-280,20034,01230,0531.70%-3,959
ENLIVEN THERAPEUTICS INC200,0000-200,0004,0940—-4,094
BIOMEA FUSION INC(BMEA)3,570,8720-3,570,8727,2130—-7,213
GH RESEARCH PLC(GHRS)1,916,4391,300,000-616,43927,40516,5100.94%-10,895
CORBUS PHARMACEUTICALS HLDGS(CRBP)2,375,0002,344,971-30,02930,04419,0881.08%-10,956
JANUX THERAPEUTICS INC(JANX)850,000650,000-200,00020,7748,9700.51%-11,804
AVIDITY BIOSCIENCES INC300,0000-300,00013,0710—-13,071
CENTESSA PHARMACEUTICALS PLC1,925,0001,325,000-600,00046,68133,1381.88%-13,543
INSMED INC(INSM)430,000275,000-155,00061,92447,8612.71%-14,063
METSERA INC400,0000-400,00020,9320—-20,932
KORRO BIO INC(KRRO)465,0000-465,00022,2690—-22,269
CG ONCOLOGY INC(CGON)625,0000-625,00025,1750—-25,175
NEWAMSTERDAM PHARMA COMPANY
ORDINARY SHARES
2,175,0001,000,000-1,175,00061,85735,0801.99%-26,777
ARCELLX INC
COMMON STOCK
775,0000-775,00063,6280—-63,627
Page 1 of 1
Cormorant Asset Management, LP — 13F Holdings — Q4 2025 | TickerTrail